TipRanks
Advertisement

BUSA - ETF AI Analysis

Compare

Top Page

BUSA

Brandes U.S. Value ETF (BUSA)

Rating:71Outperform
Price Target:
BUSA, the Brandes U.S. Value ETF, has a solid overall rating that reflects a portfolio of generally strong, established companies. Standout holdings like Merck and Intercontinental Exchange support the fund’s quality through robust financial performance, attractive growth prospects, and positive strategic initiatives, while names like Chevron and Pfizer add income potential but face challenges such as weaker recent revenue trends and legal or integration risks. The main risk factor is that several holdings show signs of potential overvaluation or mixed technical signals, which could increase volatility even though the overall portfolio remains relatively strong.
Positive Factors
Solid Recent Performance
The ETF has delivered strong gains so far this year and in recent months, showing positive momentum.
Balanced Sector Mix
Holdings spread across health care, financials, industrials, technology, and other sectors help reduce the impact of weakness in any single industry.
Strong Contributors Among Top Holdings
Several major positions, including large financial and health care companies, have shown strong performance, supporting the fund’s overall returns.
Negative Factors
Higher Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which can modestly reduce long-term returns compared with lower-cost options.
Heavy U.S. Concentration
With almost all assets in U.S. companies, the ETF offers little geographic diversification and is highly tied to the U.S. market.
Mixed Performance Within Top Holdings
A few of the largest positions, particularly in health care and financials, have shown weak or negative performance, which can drag on the fund if those trends continue.

BUSA vs. SPDR S&P 500 ETF (SPY)

BUSA Summary

The Brandes U.S. Value ETF (BUSA) is a fund that invests in a wide range of U.S. companies that its managers believe are currently undervalued. It doesn’t track a specific index, but instead follows a value investing approach, focusing on stocks that may be out of favor but still have solid business fundamentals. The ETF holds well-known names like Bank of America and Alphabet (Google), and spreads money across sectors such as health care, financials, and industrials. Investors might choose BUSA for diversification and potential long-term growth, but should know its value stocks can go up and down with the broader market and may stay out of favor for long periods.
How much will it cost me?The Brandes U.S. Value ETF (BUSA) has an expense ratio of 0.6%, meaning you’ll pay $6 per year for every $1,000 invested. This is higher than average because it is actively managed, with experts selecting undervalued stocks rather than following a passive index.
What would affect this ETF?The Brandes U.S. Value ETF could benefit from a recovery in undervalued sectors like Financials and Health Care, especially if economic conditions improve or interest rates stabilize, supporting growth in these industries. However, rising interest rates or regulatory changes in key sectors like Technology and Energy could negatively impact some of its top holdings, such as Bank of America and Chevron. The ETF's focus on U.S. equities means it is sensitive to domestic economic trends and policy shifts.

BUSA Top 10 Holdings

BUSA is leaning heavily on U.S. health care and financials, and that’s where the story starts. Merck and Pfizer have been rising and look like key engines for the fund, while Becton Dickinson is steadier but not really adding much spark. On the financial side, Bank of America and PNC have been generally supportive, though their momentum has cooled recently. Cigna and Equifax are more of a mixed bag, occasionally dragging on returns. Overall, this is a U.S.-only, value-tilted portfolio, with performance largely riding on a handful of big health care and financial names.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Becton Dickinson2.93%$9.30M$49.53B-3.71%
67
Neutral
Merck & Company2.79%$8.88M$357.52B80.48%
80
Outperform
Bank of America2.55%$8.11M$404.88B11.60%
72
Outperform
Cigna2.54%$8.08M$74.11B-6.04%
72
Outperform
Textron2.53%$8.05M$13.88B-3.59%
75
Outperform
SS&C Technologies Holdings2.33%$7.40M$18.90B-10.32%
78
Outperform
Chevron2.16%$6.87M$417.95B33.20%
71
Outperform
Pfizer2.14%$6.81M$156.51B14.45%
74
Outperform
Alphabet Class C2.11%$6.70M$4.17T34.65%
82
Outperform
PNC Financial2.09%$6.65M$92.35B12.48%
71
Outperform

BUSA Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price
Price Trends
50DMA
41.43
Negative
100DMA
40.22
Positive
200DMA
38.83
Positive
Market Momentum
MACD
-0.18
Positive
RSI
34.36
Neutral
STOCH
3.94
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BUSA, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 41.92, equal to the 50-day MA of 41.43, and equal to the 200-day MA of 38.83, indicating a neutral trend. The MACD of -0.18 indicates Positive momentum. The RSI at 34.36 is Neutral, neither overbought nor oversold. The STOCH value of 3.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BUSA.

BUSA Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$318.16M0.60%
71
Outperform
$938.85M0.13%
69
Neutral
$667.80M0.40%
75
Outperform
$616.85M0.28%
72
Outperform
$417.73M0.38%
71
Outperform
$252.40M0.50%
69
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BUSA
Brandes U.S. Value ETF
40.59
6.30
18.37%
VFVA
Vanguard U.S. Value Factor ETF
LSVD
LSV Disciplined Value ETF
QVAL
Alpha Architect U.S. Quantitative Value ETF
AIVL
WisdomTree U.S. AI Enhanced Value Fund
GVLU
Gotham 1000 Value ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement